FIT Biotech Oy: CORRECTION TO THE REGISTRATION DATES: NOTICE CONVENING AN EXTRAORDINARY GENERAL MEETING OF FIT BIOTECH OY NOVEMBER 23, 2017

Press release EGM Invitation 23112017_ENG


Company release November 29, 2017 at 3:30 PM

 

CORRECTION TO THE REGISTRATION DATES: NOTICE CONVENING AN EXTRAORDINARY GENERAL MEETING OF FIT BIOTECH OY NOVEMBER 23, 2017

 

  1. Shareholders registered in the shareholders’ register

Each shareholder, who is registered on December 1, 2017, the record date of the meeting, in the Company’s shareholders’ register maintained by Euroclear Finland Ltd, has the right to participate in the EGM. A shareholder whose shares are registered on his/her personal Finnish book-entry account is registered in the shareholders’ register of the Company.

A shareholder who is registered in the shareholders’ register of the Company and who wants to participate in the EGM has to register for the meeting no later than at 10:00 am (Finnish time) on December 11, 2017.

2.      Holders of nominee-registered shares

A holder of nominee registered shares has the right to participate in the EGM based on the shares that would entitle him/her to be registered on December 11, 2017 in the shareholders’ register maintained by Euroclear Finland Ltd. The right to participate in the EGM also requires that the shareholder has on the basis of such shares been temporarily registered into the shareholders’ register held by Euroclear Finland Ltd at the latest by December 11, 2017 at 10:00 am (Finnish time).

Helsinki, November 29, 2017

FIT Biotech Oy

Board of Directors

For further information:
Chairman of the Board of Directors Rabbe Slätis
Tel: +358 40 840 6749 
E-mail: rabbe.slatis@fitbiotech.com

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media